updates in the treatment landscape of p53-mutated aml/mds
Published 2 years ago • 472 plays • Length 1:26Download video MP4
Download video MP3
Similar videos
-
8:14
progress in the treatment of tp53 mutated aml
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
3:19
an overview of novel treatment approaches in tp53-mutated aml
-
2:24
the challenges of treating tp53-mutated aml and mds
-
2:23
improving treatment for patients with tp53-mutated myeloid malignancies
-
1:13
targeting p53 in mds
-
1:27
treatment options for patients with tp53-mutated aml
-
1:36
eprenetapopt plus venetoclax and azacitidine in the treatment of tp53-mutated aml
-
7:11
treatment of older mds patients with bmt (bone marrow transplantation)
-
2:43
magrolimab azacitidine in tp53-mutant aml
-
4:28
understanding myelodysplastic syndromes (mds)
-
1:59
depth of molecular response in patients with tp53m mds & aml treated with magrolimab and azacitidine
-
0:58
options available to patients with tp53-mutated mds beyond stem cell transplantation
-
5:16
an analysis of tp53 mutation in aml and hr-mds
-
3:00
apr-246 in tp53 mutated mds and aml
-
1:57
tolerability and efficacy of magrolimab plus azacitidine in tp53-mutated aml patients
-
1:40
outcomes of allohsct in tp53-mutated aml and mds
-
2:26
impact of allelic state on os in tp53-mutant aml and hr-mds
-
3:22
is tp53-mutated high-risk mds the same disease as tp53-mutated aml?
-
1:13
the challenges of treating patients with mpns who possess a tp53 mutation
-
2:58
long-term follow-up: phase ii study of apr-246 aza in tp53-mutated mds & aml
-
0:44
unmet needs in aml: tp53 mutations and maintenance therapy